Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study
Articolo
Data di Pubblicazione:
2010
Citazione:
Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study / F. Mancini, A. Cianciosi, N. Persico, F. Facchinetti, P. Busacchi, C. Battaglia. - In: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. - ISSN 0002-9378. - 202:2(2010 Feb), pp. 169.e1-169.e8. [10.1016/j.ajog.2009.09.038]
Abstract:
OBJECTIVE: We sought to verify if an oral contraceptive (OC) containing drospirenone affects the cardiovascular risk of patients with polycystic ovary syndrome (PCOS).
STUDY DESIGN: A total of 28 women with PCOS (16 lean [group A] and 12 overweight [group B]) were assessed at baseline and after 6 months therapy with an OC. Leptin, homocysteine, endothelin-1, and flow-mediated dilatation of brachial artery were measured.
RESULTS: The brachial artery diameter and the pulsatility index, after the reactive hyperemia, did not change in group A; it improved significantly in group B after 6 months of treatment. At baseline and after therapy the plasma levels of homocysteine and endothelin-1 did not differ among the groups. Leptin was significantly lower at baseline in group A compared to group B.
CONCLUSION: The OC containing drospirenone does not seem to affect the surrogate markers of cardiovascular risk in lean patients with PCOS.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Adolescent; Adult; Androstenes; Brachial Artery; Cardiovascular Diseases; Contraceptives, Oral; Endothelin-1; Female; Homocysteine; Humans; Insulin; Insulin Resistance; Leptin; Mineralocorticoid Receptor Antagonists; Obesity; Pilot Projects; Polycystic Ovary Syndrome
Elenco autori:
F. Mancini, A. Cianciosi, N. Persico, F. Facchinetti, P. Busacchi, C. Battaglia
Link alla scheda completa: